Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments

Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments

Abstract Background Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for detection of minimal residual disease (MRD), monitoring treatment response, and early detection of recurrence in cancer patients. In this study, we explored the utility of ctDNA‐based MRD detec...

Full description

Bibliographic Details
Main Authors: Youjin Oh, Sung Mi Yoon, Jeeyeon Lee, Joo Hee Park, Soowon Lee, Timothy Hong, Liam Il‐young Chung, Sumedha Sudhaman, Timothy Riddell, Charuta C. Palsuledesai, Michael Krainock, Minetta C. Liu, Young Kwang Chae
Format: Article
Language:English
Published: Wiley 2024-05-01
Series:Thoracic Cancer
Subjects:
biomarker
ctDNA
lung cancer
molecular residual disease
prognosis
Online Access:https://doi.org/10.1111/1759-7714.15281

Internet

https://doi.org/10.1111/1759-7714.15281

Similar Items